Cannabis dosing and administration for sleep: a systematic review

被引:16
|
作者
Velzeboer, Rob [1 ]
Malas, Adeeb [2 ]
Boerkoel, Pierre [3 ]
Cullen, Katie [3 ]
Hawkins, Michelle [3 ]
Roesler, Jordanna [4 ]
Lai, Wayne Wei-Ku [3 ,5 ]
机构
[1] Tranq Sleep Care, Clin Res, 215-3030 Pandosy St, Kelowna, BC V1Y 1W2, Canada
[2] Univ British Columbia, Fac Med, Dept Psychiat, Vancouver, BC, Canada
[3] Univ British Columbia, Fac Med, Vancouver, BC, Canada
[4] Univ British Columbia, Fac Med, Dept Dermatol, Vancouver, BC, Canada
[5] Tranq Sleep Care, Kelowna, BC, Canada
关键词
cannabis; cannabidiol; tetrahydracannabinol; CBD; THC; marijuana; sleep; insomnia; DOUBLE-BLIND; MEDICAL CANNABIS; MEDICINAL CANNABIS; OPEN-LABEL; OROMUCOSAL SPRAY; ADD-ON; NABILONE; EFFICACY; DELTA-9-TETRAHYDROCANNABINOL; PHARMACOLOGY;
D O I
10.1093/sleep/zsac218
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Study objectives As cannabis is increasingly used to treat sleep disorders, we performed a systematic review to examine the effects of cannabis on sleep and to guide cannabis prescribers in their recommendations to patients, specifically focusing on dosing. Methods We searched EMBASE, Medline, and Web of Science and identified 4550 studies for screening. Five hundred sixty-eight studies were selected for full-text review and 31 were included for analysis. Study results were considered positive based on improvements in sleep architecture or subjective sleep quality. Bias in randomized controlled trials was assessed using Cochrane Risk of Bias tool 2.0. Results Sleep improvements were seen in 7 out of 19 randomized studies and in 7 out of 12 uncontrolled trials. There were no significant differences between the effects of tetrahydrocannabinol and cannabidiol. Cannabis showed most promise at improving sleep in patients with pain-related disorders, as compared to those with neurologic, psychiatric, or sleep disorders, and showed no significant effects on healthy participants' sleep. While subjective improvements in sleep quality were often observed, diagnostic testing showed no improvements in sleep architecture. Adverse events included headaches, sedation, and dizziness, and occurred more frequently at higher doses, though no serious adverse events were observed. Conclusion High-quality evidence to support cannabis use for sleep remains limited. Heterogeneity in cannabis types, doses, timing of administration, and sleep outcome measures limit the ability to make specific dosing recommendations.
引用
收藏
页数:2
相关论文
共 50 条
  • [31] Cannabis for the Treatment of Fibromyalgia: A Systematic Review
    Strand, Natalie H.
    Maloney, Jillian
    Kraus, Molly
    Wie, Christopher
    Turkiewicz, Michal
    Gomez, Diego A.
    Adeleye, Olufunmilola
    Harbell, Monica W.
    BIOMEDICINES, 2023, 11 (06)
  • [32] Cannabis and sleep disorders: not ready for prime time? A qualitative scoping review
    Amaral, Caio
    Carvalho, Carolina
    Scaranelo, Anabel
    Chapman, Kenneth
    Chatkin, Jose
    Ferreira, Ivone
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2023, 19 (05): : 975 - 990
  • [33] Cannabis-based products for pediatric epilepsy: A systematic review
    Elliott, Jesse
    DeJean, Deirdre
    Clifford, Tammy
    Coyle, Doug
    Potter, Beth K.
    Skidmore, Becky
    Alexander, Christine
    Repetski, Alexander E.
    Shukla, Vijay
    McCoy, Blathnaid
    Wells, George A.
    EPILEPSIA, 2019, 60 (01) : 6 - 19
  • [34] The Effectiveness of Cannabis and Cannabis Derivatives in Treating Lower Back Pain in the Aged Population: A Systematic Review
    Senderovich, Helen
    Wagman, Hayley
    Zhang, Dennis
    Vinoraj, Danusha
    Waicus, Sarah
    GERONTOLOGY, 2022, 68 (06) : 612 - 624
  • [35] Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies
    Suraev, Anastasia S.
    Marshall, Nathaniel S.
    Vandrey, Ryan
    McCartney, Danielle
    Benson, Melissa J.
    McGregor, Iain S.
    Grunstein, Ronald R.
    Hoyos, Camilla M.
    SLEEP MEDICINE REVIEWS, 2020, 53
  • [36] Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review
    Poyatos, Lourdes
    Pilar Perez-Acevedo, Ana
    Papaseit, Esther
    Perez-Mana, Clara
    Martin, Soraya
    Hladun, Olga
    Siles, Adria
    Torrens, Marta
    Paolo Busardo, Francesco
    Farre, Magi
    MEDICINA-LITHUANIA, 2020, 56 (06): : 1 - 28
  • [37] The Association Between Cannabis Use and Schizophrenia: Causative or Curative? A Systematic Review
    Patel, Shweta J.
    Khan, Sahar
    Saipavankumar, M.
    Hamid, Pousettef
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (07)
  • [38] A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
    Lim, Keane
    See, Yuen Mei
    Lee, Jimmy
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2017, 15 (04) : 301 - 312
  • [39] A Systematic Review of Medical Cannabinoids Dosing in Human
    Campos, David A.
    Mendivil, Edgar J.
    Romano, Mario
    Garcia, Mariano
    Martinez, Miriam E.
    CLINICAL THERAPEUTICS, 2022, 44 (12) : e39 - e58
  • [40] A systematic review of cannabidiol dosing in clinical populations
    Millar, S. A.
    Stone, N. L.
    Bellman, Z. D.
    Yates, A. S.
    England, T. J.
    O'Sullivan, S. E.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 1888 - 1900